These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 19773529)

  • 1. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
    Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
    J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
    Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
    Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
    Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
    J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
    Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
    J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
    Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
    J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel and Selective Nociceptin Receptor (NOP) Agonist (1-(1-((cis)-4-isopropylcyclohexyl)piperidin-4-yl)-1H-indol-2-yl)methanol (AT-312) Decreases Acquisition of Ethanol-Induced Conditioned Place Preference in Mice.
    Zaveri NT; Marquez PV; Meyer ME; Polgar WE; Hamid A; Lutfy K
    Alcohol Clin Exp Res; 2018 Feb; 42(2):461-471. PubMed ID: 29215139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
    Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
    Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TH-030418: a potent long-acting opioid analgesic with low dependence liability.
    Yu G; Yan LD; Li YL; Wen Q; Dong HJ; Gong ZH
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Aug; 384(2):125-31. PubMed ID: 21594658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Buprenorphine Analogue BU10119 Attenuates Drug-Primed and Stress-Induced Cocaine Reinstatement in Mice.
    Hillhouse TM; Olson KM; Hallahan JE; Rysztak LG; Sears BF; Meurice C; Ostovar M; Koppenhaver PO; West JL; Jutkiewicz EM; Husbands SM; Traynor JR
    J Pharmacol Exp Ther; 2021 Sep; 378(3):287-299. PubMed ID: 34183434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
    Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
    Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships.
    Mustazza C; Pieretti S; Marzoli F
    Curr Med Chem; 2018; 25(20):2353-2384. PubMed ID: 29332567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
    Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
    J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activities of mixed NOP and mu-opioid receptor ligands.
    Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
    Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
    Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
    Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The opioid receptor pharmacology of GSK1521498 compared to other ligands with differential effects on compulsive reward-related behaviours.
    Kelly E; Mundell SJ; Sava A; Roth AL; Felici A; Maltby K; Nathan PJ; Bullmore ET; Henderson G
    Psychopharmacology (Berl); 2015 Jan; 232(1):305-14. PubMed ID: 24973897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of conditioned place preference or reinstatement with bivalent ligands containing mu-opioid receptor agonist and delta-opioid receptor antagonist pharmacophores.
    Lenard NR; Daniels DJ; Portoghese PS; Roerig SC
    Eur J Pharmacol; 2007 Jul; 566(1-3):75-82. PubMed ID: 17383633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I.
    Zaveri NT; Jiang F; Olsen C; Polgar WE; Toll L
    Bioorg Med Chem Lett; 2013 Jun; 23(11):3308-13. PubMed ID: 23623415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
    Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
    Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective and high affinity labeling of neuronal and recombinant nociceptin receptors with the hexapeptide radioprobe [(3)H]Ac-RYYRIK-ol.
    Bojnik E; Farkas J; Magyar A; Tömböly C; Güçlü U; Gündüz O; Borsodi A; Corbani M; Benyhe S
    Neurochem Int; 2009 Dec; 55(7):458-66. PubMed ID: 19414055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.